Lasa Supergenerics Ltd. (IN:LASA)
:LASA
Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹11.33
-₹1.79(-6.22%)
At close: 4:00 PM EST
₹11.33
-₹1.79(-6.22%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹19.65
Previous CloseN/A
Volume56.48K
Average Volume (3M)39.13K
Market Cap
₹402.31M
Enterprise Value₹476.32M
Total Cash (Recent Filing)₹6.96M
Total Debt (Recent Filing)₹73.38M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.08
Price to Sales (P/S)0.63
P/FCF Ratio-32.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API Manufacturing Business ModelLASA's core B2B API manufacturing model serves pharmaceutical companies, creating structurally recurring demand from drug makers. This customer-driven, volume-based revenue model is durable over months as finished-dose producers continuously source APIs, supporting baseline revenue potential if operations stabilize.
Manageable Leverage And Solid Equity RatioA moderate debt load and relatively strong equity ratio provide financial flexibility during a turnaround window. Manageable leverage reduces near-term insolvency risk and supports access to financing or working capital facilities over the next several months while management addresses operational issues.
Exposure To Specialty & Generic Pharmaceutical SectorOperating in the specialty and generic drug segment ties LASA to a large, structurally resilient market where outsourcing of API production is common. Long-term pharmaceutical manufacturing needs and cost-driven outsourcing trends underpin sustained addressable demand for API suppliers over a multi-month horizon.
Bears Say
Steep Multi-year Revenue DeclineA pronounced, sustained drop in revenue reduces scale economics and weakens the firm's ability to cover fixed manufacturing costs. Continued top-line erosion constrains recovery options, limits reinvestment capacity, and extends the timeline required to restore sustainable profitability absent a clear reversal.
Deteriorating Margins And Persistent Net LossesConsistent negative margins and net losses erode retained earnings and degrade return metrics. Persisting unprofitability undermines internal funding for R&D, capex, or working capital, pressures stakeholder confidence, and may force restructuring or asset sales to restore viability over the medium term.
Negative Operating And Free Cash FlowNegative operating cash flow and free cash flow create ongoing liquidity strain, making it difficult to fund operations, pay suppliers, or invest. Even with moderate leverage, sustained cash burn increases dependence on external financing and heightens execution risk for any turnaround initiatives.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹19.65 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹402.31M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 33 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on Feb 13, 2026. The company reported -₹0.51 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.51.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.51 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.032%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―